IRIS
BORDI, Paola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.339
AS - Asia 3.188
EU - Europa 1.944
SA - Sud America 476
AF - Africa 168
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 4
Totale 9.125
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.231
SG - Singapore 1.067
CN - Cina 707
IT - Italia 568
VN - Vietnam 539
BR - Brasile 362
SE - Svezia 287
IE - Irlanda 274
HK - Hong Kong 272
BD - Bangladesh 223
DE - Germania 168
FR - Francia 136
ZA - Sudafrica 106
NL - Olanda 105
IN - India 83
RU - Federazione Russa 77
GB - Regno Unito 67
AT - Austria 63
CA - Canada 62
FI - Finlandia 59
AR - Argentina 44
TR - Turchia 38
ID - Indonesia 36
JP - Giappone 30
PH - Filippine 25
IQ - Iraq 23
KR - Corea 23
ES - Italia 21
MX - Messico 21
CO - Colombia 18
EC - Ecuador 18
CI - Costa d'Avorio 17
PK - Pakistan 17
CZ - Repubblica Ceca 16
BE - Belgio 15
UA - Ucraina 15
PL - Polonia 14
UZ - Uzbekistan 13
IR - Iran 12
TN - Tunisia 12
MA - Marocco 11
VE - Venezuela 11
CL - Cile 10
LT - Lituania 10
TH - Thailandia 9
TW - Taiwan 9
JO - Giordania 8
MY - Malesia 8
SA - Arabia Saudita 8
EG - Egitto 7
KZ - Kazakistan 7
AU - Australia 6
LU - Lussemburgo 6
AL - Albania 5
AZ - Azerbaigian 5
DO - Repubblica Dominicana 5
IL - Israele 5
BG - Bulgaria 4
CR - Costa Rica 4
ET - Etiopia 4
GR - Grecia 4
NP - Nepal 4
OM - Oman 4
PY - Paraguay 4
DK - Danimarca 3
GT - Guatemala 3
KE - Kenya 3
MD - Moldavia 3
NI - Nicaragua 3
PE - Perù 3
PT - Portogallo 3
RO - Romania 3
SN - Senegal 3
XK - ???statistics.table.value.countryCode.XK??? 3
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
CH - Svizzera 2
GY - Guiana 2
HU - Ungheria 2
JM - Giamaica 2
KG - Kirghizistan 2
LV - Lettonia 2
NO - Norvegia 2
PA - Panama 2
QA - Qatar 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
BB - Barbados 1
BO - Bolivia 1
BY - Bielorussia 1
CG - Congo 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
DZ - Algeria 1
GE - Georgia 1
HN - Honduras 1
Totale 9.113
Salva come PNG Salva come JPEG
Città #
Singapore 600
Ashburn 510
Dallas 355
San Jose 335
Chandler 302
Dublin 270
Hong Kong 259
Beijing 176
Santa Clara 174
Ho Chi Minh City 156
Boardman 126
Hanoi 126
New York 119
Los Angeles 106
Parma 103
Johannesburg 102
Shanghai 89
Munich 84
Lauterbourg 67
Ann Arbor 60
Milan 58
Council Bluffs 51
Vienna 51
Princeton 46
Bologna 45
Hefei 39
Moscow 36
São Paulo 36
Buffalo 31
Chicago 31
Marseille 31
Helsinki 29
Des Moines 28
Columbus 27
Nanjing 25
Wilmington 25
Frankfurt am Main 22
Haiphong 22
Montreal 21
Rome 21
Verona 21
Atlanta 20
Da Nang 20
Seattle 20
Tokyo 20
Turku 20
The Dalles 19
Denver 18
Jakarta 18
Abidjan 17
Bremen 17
Dearborn 17
Nuremberg 16
Seoul 16
Toronto 15
Izmir 14
London 14
Modena 14
Reggio Emilia 14
Amsterdam 13
Biên Hòa 13
Chennai 13
Guangzhou 13
Jinan 13
Istanbul 12
Redondo Beach 12
Warsaw 12
West Jordan 12
Brno 11
Brooklyn 11
Poplar 11
Bengaluru 10
Changsha 10
Hải Dương 10
Rio de Janeiro 10
Boston 9
Brasília 9
Brussels 9
Mumbai 9
Redmond 9
Stockholm 9
Tashkent 9
Tianjin 9
Trento 9
Amman 8
Baghdad 8
Chongqing 8
Houston 8
Kunming 8
Lahore 8
Manchester 8
Phoenix 8
Pune 8
Belo Horizonte 7
Charlotte 7
Mexico City 7
Orem 7
Quảng Ngãi 7
Buenos Aires 6
Curitiba 6
Totale 5.510
Salva come PNG Salva come JPEG
Nome #
1328P Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients 218
227P Sexual dimorphism in immune profile of early and advanced NSCLC 202
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy 202
The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors 195
LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS 184
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC 179
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC 178
Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 176
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients 174
CLINICAL PREDICTORS OF 30-DAY MORTALITY IN HOSPITALIZED PATIENTS WITH LUNG CANCER: A RETROSPECTIVE SINGLE-CENTER OBSERVATIONAL STUDY 172
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 167
Emergence of a HER2-amplified clone during disease progression in an ALK-rearranged NSCLC patient treated with ALK-inhibitors: A case report 167
Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature 162
Widespread Nivolumab-induced Enteropathy in a Long Responder Non–Small-cell Lung Cancer Patient 161
2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients 157
Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first-line immunotherapy-based regimens 157
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 155
From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC 154
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 151
Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC 145
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 145
2125P Potential ROle of hypoVItaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): A prospective observational study 144
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The practice study 144
P1.15-04 Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 142
Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs) 142
Longitudinal blood immune-inflammatory and radiomic profiling to decode different patterns acquired resistance to immunotherapy in patients with NSCLC 139
Monitoring cfDNA in plasma and in other liquid biopsies of advanced EGFR mutated NSCLC patients: A pilot study and a review of the literature 139
Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with Nivolumab 138
Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinib 137
5P Blood immune-inflammatory dynamic unveils distinctive irAE features in ICI treated NSCLC 136
Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer 134
A case series of non-small cell lung cancer patients with EGFR or HER2 exon 20 insertion in Li Fraumeni syndrome 134
1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC 131
1599P Clinical predictors of 30-day mortality in hospitalized patients with lung cancer: A retrospective single-center observational study 130
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 130
ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin 129
Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: A study on circulating tumor DNA 127
2PD Monitoring of secondary drug resistance mutations in circulating tumor DNA of patients with advanced ALK positive NSCLC 126
Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer 122
Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study 118
Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy 118
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 117
Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment 116
L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC 112
Thirty-day mortality in hospitalised patients with lung cancer: incidence and predictors 110
EP.15B.05 Predictors of 30-Day Mortality after Systemic Therapy in Hospitalized Lung Cancer Patients: A Retrospective Single-Center Observational Study 106
Prognostic immunoinflammatory and transcriptomic profiles in patients with pleural mesothelioma undergoing immunotherapy 104
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study 102
Crizotinib resensitization by compound mutation 102
NGS detection of gene rearrangements and METexon14 mutations in liquid biopsy of advanced NSCLC patients: A study of two Italian centers 101
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients 98
Dynamic evaluation of circulating mirna profile in egfr‐ mutated nsclc patients treated with egfr‐tkis 95
Circulating tumor DNA dynamic variation predicts sotorasib efficacy in KRASp.G12C-mutated advanced non-small cell lung cancer 94
Narrative literature and cancer: improving the doctor-patient relationship 93
Liquid Biopsy and 18F-FDG PET/CT Derived Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC 92
P57.08 High Performance Radiomic Classifier to Predict the Response to Immunotherapy in Advanced NSCLC 92
A prospective study on clinicians’ attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020) 91
Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study 89
Type 2 diabetes mellitus and efficacy outcomes from immune checkpoint blockade in patients with cancer 86
Dissecting the impact of Controlling Nutritional Status (CONUT) score on survival outcomes and immune-inflammatory profiles in patients with advanced NSCLC undergoing first-line immunotherapy 85
Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian study 85
Transient asymptomatic pulmonary opacities and interstitial lung disease in EGFR-mutated non-small cell lung cancer treated with osimertinib 85
Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients 84
Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study 80
Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: Review on emerged mechanisms of resistance 79
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: Implications for personalised treatment 70
Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: Patient selection and perspectives 68
Enteral administration of tkis: Report of a response to ceritinib in an alk-positive nsclc patient and literature review 67
Gene mutations in small-cell lung cancer (SCLC): Results of a panel of 6 genes in a cohort of Italian patients 64
Overcoming T790M-driven acquired resistance to EGFR-TKIs in NSCLC with afatinib: A case report 63
Emerging role of gefitinib in the treatmentof non-small-cell lung cancer (NSCLC) 63
Genetic, tissue and circulating PD-L1 profiling to predict the response to immuno-checkpoint inhibitors in advanced NSCLC 58
Metabolic complete response with vinflunine as second-line therapy in a kidney-transplanted patient with advanced urothelial carcinoma: A case report 55
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed 53
Radiotherapy of non-small-cell lung cancer in the era of EGFR gene mutations and EGF receptor tyrosine kinase inhibitors 51
Efficacy and safety of long-term tolvaptan treatment in a patient with SCLC and SIADH 49
Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRASG12C inhibitors in NSCLC 20
Analisi mutazionale del DNA circolante plasmatico nelle neoplasie polmonari EGFR mutate. Risultati di uno studio prospettico 2
Totale 9.242
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.668
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.668
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20215 0 0 0 0 0 0 0 0 0 0 0 5
2021/2022255 2 10 6 17 5 6 48 16 8 4 25 108
2022/20231.119 128 140 58 93 115 120 16 65 311 4 51 18
2023/2024632 30 29 20 22 52 133 67 42 42 44 44 107
2024/20251.868 50 115 160 142 147 180 137 81 169 173 145 369
2025/20264.938 373 343 697 490 588 258 442 232 636 365 333 181
Totale 9.242